Anyone who has followed the biopharma sector over the past decade knows that big pharma's lust for monoclonal antibody technology isn't going away any time soon. But a recent report and webinar by Deloitte Recap LLC, which broke down more than 1,000 deals over the last 10 years, showed some unexpected trends for companies working in the antibody space.